Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report

techtransfer.org.au

SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH (SCOPR) 2019 REPORT

Survey and report delivered by FOREWORD

There is an ever-present imperative to capture the commercial value of our research endeavour for our future wellbeing. To do so strategically, decision makers from laboratory, institutional and government levels need insights into how the research sector is currently engaging with industry to transfer knowledge and innovation, and thereby deliver benefits to our society from the fruits of our research.

For many years in Australia there has been a focus on improving innovation metrics, thus I am delighted to acknowledge the initiative of gemaker and Knowledge Commercialisation Australasia (KCA) in producing the inaugural Survey of Commercial Outcomes from Public Research (SCOPR).

The SCOPR takes its lead from the National Survey of Research Commercialisation (NSRC) produced since 2000 by the Department of Industry, Science, Energy and Resources. To avoid duplication, the Department has decided to cease the NSRC and will work with KCA to share knowledge, and access data collected by SCOPR.

As we face the COVID-19 pandemic, effective knowledge transfer is more important than ever, so I hope that this report will spur our research institutions to even greater achievements.

Realising effective knowledge transfer will depend on having skilled commercialisation professionals who can help researchers turn great ideas into beneficial products and services. I applaud KCA’s support for technology transfer professionals whose impact is the subject of this extremely valuable survey and I thank all SCOPR participants.

Dr Alan Finkel Australia’s Chief Scientist

September 2020 CONTENTS

Introduction 4 SCOPR respondents 2019 5 SCOPR measures 6 Research commercialisation outcomes: aggregated data 2017-19 7-8 Start-ups / spin-outs showcase 9 Case study 1 10 GRAPHS OF 2017-19 DATA Research income 11 Research expenditure 12 Researchers (full-time equivalent) 13 Case study 2 14 Invention disclosures 15 New and active patent families 16 New and active non-patented IP 17 Case study 3 18 New and active licences, options and assignments 19 Commercialisation revenue 20 Start-up and spin-out companies 21 Case study 4 22

DISCLAIMER This report has been prepared solely for KCA for the purpose of providing an analysis of the commercial activities of Australasian public research organisations. As such, neither KCA or gemaker undertakes responsibility in any way whatsoever to any person or organisation for reliance on any information set out in this report, including any errors or omissions here-in, arising through negligence or otherwise, however caused.

The Survey of Commercialisation Outcomes from Public Research (SCOPR) is an initiative of Knowledge Commercialisation Australasia (KCA), the peak body representing technology transfer professionals and their organisations in Australia and New Zealand. SCOPR collects data from Australian and New Zealand universities, medical research institutes and publicly funded research agencies. It enables national and international benchmarking of respondents and helps to inform decisions by research organisations, government and industry stakeholders seeking to enhance industry engagement and research commercialisation. KCA has developed SCOPR to replace the National Survey of Research Commercialisation (NSRC) produced from 2000-2016 by the Department of Industry, Science and Resources. To avoid duplication in metrics and survey population, the Department has decided to cease the NSRC and will work with KCA to share the critical information collected by SCOPR. The inaugural SCOPR covers the calendar years 2017, 2018 and 2019. Forty-nine Australian and New Zealand research organisations responded to the survey. SCOPR is overseen by a committee representing KCA, the Group of Eight (Go8), the Association of Australian Medical Research Institutes (AAMRI) and KiwiNet. The survey and report have been delivered by gemaker, an award-winning Australian commercialisation consultancy, on behalf of KCA. KCA has led best practice in industry engagement, technology transfer and entrepreneurship for research organisations since 1978 and is a founding member of the global Alliance of Technology Transfer Professionals. KCA is honoured to support the dedicated people who work at the intersection of research and industry. Although they comprise a small proportion of the staff of any research organisation, technology transfer professional (TTPs) are key to their organisations’ real-world impact. TTPs identify researchers’ discoveries and innovations that have high potential for social benefit and commercial success and facilitate the complex and arduous journey from idea to reality, thereby ensuring that social and economic benefits result from the billions of public dollars spent each year on research. To illustrate the positive impacts of research commercialisation, this report includes four diverse case studies from SCOPR respondents – finalists in the 2020 KCA Awards, which celebrate world-class work in tech transfer. KCA is committed to SCOPR because it showcases the vital work of TTPs, measures their impact and informs strategies to continually enhance professionalism in the tech transfer sector for the benefit of researchers, industry and the wider community.

Dr Erin Rayment John Grace AO Natalie Chapman Chair KCA Chair SCOPR Committee Managing Director gemaker

AUSTRALIA 34 respondents NEW ZEALAND 15 respondents UNIVERSITIES (24) MEDICAL RESEARCH INSTITUTES (7) UNIVERSITIES (6) Auckland University of Technology Australian National University Bionics Institute of Australia Lincoln University Curtin University Black Dog Institute Massey University Edith Cowan University Centenary Institute of Cancer Medicine Victoria University of Wellington Federation University Australia and Cell Biology University of Canterbury Flinders University Hudson Institute of Medical Research University of Waikato Griffith University Telethon Kids Institute James Cook University Walter and Eliza Hall Institute of La Trobe University Medical Research MEDICAL RESEARCH INSTITUTES (2) Macquarie University Westmead Institute of Medical Malaghan Institute of Medical Research Monash University Research Health Innovation Hub Queensland University of Technology RMIT University University of Adelaide OTHER PUBLIC RESEARCH OTHER PUBLIC RESEARCH ORGANISATIONS (7) University of Queensland ORGANISATIONS (2) AgResearch Ltd University of Melbourne Australian Nuclear Science and Callaghan Innovation University of Newcastle Technology Organisation (ANSTO) Cawthron Institute University of New South Wales Commonwealth Scientific and GNS Science University of South Australia Industrial Research Organisation Institute of Environmental Science and Research (ESR) University of Southern Queensland (CSIRO) Manaaki Whenua Landcare Research University of Sydney Plant and Food Research University of Tasmania University of Western Australia OTHER RESEARCH ORGANISATION (1) University of Wollongong Western Sydney University Meat and Livestock Australia Limited

Commercialisation is managed by technology transfer staff

Full-time Patented equivalent (FTE) intellectual researchers property (IP)

IP licences, Research Research Invention options and Commercialisation income expenditure disclosures assignments Spin-out and revenue Non- (LOAs) start-up patented IP companies

For universities, this Research An invention A patent grants an Licences may grant Spin-out and start- Commercialisation includes research expenditure is disclosure describes inventor exclusive another party (licensee) up companies are revenue is gross income income in HERDC the total spent an invention in rights to the IP for a the rights to make/sell/ founded through from all LOAs, material Categories 1 (Aus on research, detail and is used designated period use the IP owned by the licensing or transfers and sales of competitive grants), whether funded to determine its in exchange for a licensor. assignment of IP. products or services 2 (other public from general creators, novelty comprehensive based on expertise or IP, Options grant the sector), 3 (industry organisational and potential for disclosure of the Spin-outs are plus cashed-in equity, potential licensee time and other) and funds or through social impact and/or invention. launched by minus any cost of to evaluate the IP and 4 (Cooperative public or private commercialisation. the research acquiring the equity. Non-patented negotiate the terms of a Research Centres). grants or contracts. organisation. Intellectual property IP includes plant licence agreement. Excluded: research funding, For other is novel proprietary breeders’ rights, copyright income, non-cash Assignments convey all Start-ups are organisations, knowledge. It can be confidential know-how, value exchanged for equity rights and title to, and launched by other holdings, value of equity not research income an invention, trade registered designs, interest in, the licensed parties through cashed-in, patent expense includes equivalent mark, design, brand, circuit layouts, trade reimbursement, consultancies IP to the assignee. licensing or types. or application of an secrets, software, and contract research – unless idea. trademarks, apps etc. assignment of IP. or until new IP is created.

Notes: Not all respondents reported data for all measures. New Zealand reported aggregated data only.

Invention New non- New patent New licences, options and disclosures patented IP applications assignments

AUSTRALIA 34 respondents

2019 1355 364 455 609

2018 1362 327 428 567

2017 1263 298 454 588

NEW ZEALAND 15 respondents 2019 274 69 144 not reported

2018 154 58 80 not reported

2017 186 47 90 not reported

Notes: Not all respondents reported data for all measures. New Zealand reported aggregated data only.

N A

New spin-outs Active spin-outs Equity Commercialisation and start-ups and start-ups holdings* revenue (AUD)

AUSTRALIA 34 respondents

2019 42 231 $261.8 M $175.9 M Notes: New spin-out and start-up companies were incorporated 2018 48 217 $178.5 M $119.4 M in 2019. Active companies were # incorporated in or before 2019. 2017 43 199 $145.8 M $451.7 M A company is active when it has sufficient financial resources to operate and make progress NEW ZEALAND 15 respondents toward stated business goals. *Total value of the equity held 2019 10 60 not reported $81.4 M by respondents in all start-ups and spin-outs. # In 2017, Walter and Eliza Hall 2018 10 50 not reported not reported Institute of Medical Research (WEHI) made a landmark deal worth $325 million – more 2017 5 45 not reported not reported details on p. 20.

Aggregated data 2019 Example companies

Amaero International Ltd (ASX:3DA) Source: Monash University Sector: Manufacturing new 42 Incorporated: 2013 231 active Company value: $55m companies Jobs created: 15 Canopus Networks Pty Ltd Source: UNSW Sector: Telecommunications Incorporated: 2018 Company value: $10M Value of equity Jobs created: 12 held by research organisations: Vaxxas Pty Ltd $261.8M Source: The University of Queensland Sector: Biotechnology Incorporated: 2011 Jobs created: 40

CSIRO’s commercialisation record 175+ $2B+ 462+ at June 2019 Companies started Total market capitalisation Jobs in from CSIRO IP of portfolio companies portfolio companies

SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH 2019 REPORT PAGE 9 Copyright © 2020 Knowledge Commercialisation Australasia RESEARCH COMMERCIALISATION CASE STUDY 1 UQ, CEPI and CSL’s COVID-19 global partnership

The WHO and the Coalition for Epidemic Preparedness Innovation (CEPI) believe the world needs multiple vaccines against the SARS-CoV-2 virus that causes COVID-19. In January 2019, The University of Queensland (UQ) was the second university in the world to be awarded CEPI funding – US$10.6 million over three years ¬– to develop its vaccine platform technology for ‘Disease X’. In January 2020, as a response to the WHO announcing COVID-19 as a pandemic, UQ was tasked by CEPI to produce a vaccine against COVID-19 and identify a partner for the late stage clinical development and distribution in an unprecedentedly short time. Proteins on the surface of SARS-CoV-2 fuse the virus to host cell membranes, a key process in infection. These proteins are the major target of a protective immune response. But when separated from the virus structure, these proteins are inherently unstable, presenting a challenge for vaccine development. To induce the correct immune response and protect a person from subsequent infection, the protein must maintain the same shape in the vaccine as it does on the live virus. UQ researchers have overcome this problem by using proprietary molecular clamp technology first conceived in 2012 and patented by UniQuest. The first human subject was dosed with UQ’s COVID-19 vaccine candidate on 13 July 2020 and a strategic partnership agreement signed with UQ, CEPI and CSL, less than 6 months after the request from CEPI. Should the first clinical trial be successful, CSL will be responsible for further clinical development, manufacture and distribution of the vaccine in accordance with the tripartite agreement. Should the development activities be successful then a vaccine could be available in 2021.

Uni QLD Newcastle Monas h Flinders Melbour ne UNSW RESEARCH INCOME 2017-19 Sydney ANU UWA For universities, this includes research income in HERDC Categories 1 (Australian competitive grants), 2 (other public sector), 3 (industry and other) and 4 (Cooperative Research Centres). For other organisations, research income includes equivalent types. Adelaide Research Income 2017-2019 ANSTO Melbour ne UNSW

Curtin Sydney Tasmania ANU UWA QUT Adelaide Telethon Kids ANSTO The following CSIRO data have Curtin been excluded from the graph due Griffith Tasmania to their magnitude:

Macqua rie QUT 2017 $1,275,170,166 2018 $1,285,168,048 UniSA Telethon Kids Griffith 2019 $1,324,489,908

WEHI Macqua rie La T robe UniSA WEHI Wollongong Notes: La T robe • Ranked by 2019 data. RMIT Wollongong • Where 2019 data were not RMIT WSU available, respondents were WSU asked to estimate income based James Cook James Cook on 2018 data. Huds on Huds on • Institutions that did not report Southern Queensland 2019 data appear at the bottom Southern Queensland Edith Cowan of the graph. Edith Cowan Centenary Institute • Where 2017 and 2018 SCOPR Black Dog Institute* Centenary Institute data conflicted with HERDC data, Westmead Institute the latter was used. Black Dog Institute Bionics Institute Federation Westmead Institute * Financial year data was reported Uni QLD instead of calendar year data. Bionics Institute Newcastle Monas h Federation Flinders $- $50,000,000 $100,000,000 $- $150,000,000 $50,000,000$50M $100,000,000$100M $200,000,000 $150,000,000$150M $200,000,000 $200M$250,000,000 $250,000,000$250M $300,000,000 $300,000,000$300M $350,000,000$350M $350,000,000 $400,000,000$400M $450,000,000$450M $400,000,000 $500,000,000$500M $550,000,000 $450,000,000 $500,000,000 $550,000,000 2017 2018 2019 2017 2018 2019

Uni QLD Newcastle Monas h Flinders RESEARCH EXPENDITURE 2017-19 Melbour ne UNSW Sydney Research expenditure is the total spent on research, whether funded from general organisational funds or through public or private grants or contracts. ANU Research Expenditure 2017-2019 UWA Uni QLD Adelaide UNSW ANSTO CSIRO Curtin UWA ANU Tasmania RMIT QUT QUT Notes: Telethon Kids Griffith UniSA # • Ranked by 2019 data. Griffith Tasmania • Where 2019 and/or 2017 data Macqua rie ANSTO were not available, university respondents were asked to UniSA MLA Telethon Kids estimate expenditure based WEHI WEHI on their 2018 ABS submission. La T robe James Cook • Institutions that did not report Wollongong Southern Queensland 2019 data appear at the Huds on bottom of the graph. RMIT WSU WSU Centenary Institute * Financial year data was reported James Cook Black Dog Institute * instead of calendar year data. Westmead Institute Huds on Bionics Institute Southern Queensland Federation Edith Cowan Melbour ne Monas h Centenary Institute Macqua rie Black Dog Institute Adelaide Westmead Institute Curtin La T robe Bionics Institute Wollongong Federation Edith Cowan

$- $100,000,000 $200,000,000 $300,000,000 $400,000,000 $500,000,000 $600,000,000 $700,000,000 $800,000,000 $900,000,000 $1,000,000,000 $1,100,000,000 $1,200,000,000 $- $50,000,000 $100,000,000$100M $150,000,000$200M $300M $200,000,000$400M $500M $250,000,000$600M $300,000,000$700M * = Financial$800M $350,000,000 year vs calendar$900Myear $1,000M $400,000,000$1,100M $450,000,000$1,200M $500,000,000 $550,000,000 Rebecca - can we change the X axis numbers to $100M etc 2017 2018 2019 # = Estimate 2019 & 2017 2017 2018 2019

Uni QLD Newcastle Monas h Flinders RESEARCHERS (FULL-TIME EQUIVALENT) 2017-2019 Researcher FTE 2017 - 2019 Melbour ne UNSW CSIRO Sydney Monas h ANU Melbour ne UWA UNSW # Adelaide Uni QLD * Adelaide ANSTO UWA Curtin Macqua rie Tasmania Griffith QUT Wollongong Telethon Kids Curtin ANU Griffith Tasmania Macqua rie QUT UniSA RMIT WEHI WSU Notes: UniSA Ranked by 2019 data. La T robe La T robe Wollongong Newcastle # Reported as at 31 RMIT WEHI March, not 31 December WSU Flinders and excludes casuals. Telethon Kids James Cook * Financial year data James Cook Huds on was reported instead of Southern Queensland Southern Queensland calendar year data. ANSTO Edith Cowan Huds on Centenary Institute Centenary Institute Black Dog Institute Westmead Institute Edith Cowan Westmead Institute Black Dog Institute* Bionics Institute Federation Federation Bionics Institute

$- $50,000,000 $100,000,000 0 200 $150,000,000400 600 800 1000$200,000,0001200 1400 1600 $250,000,0001800 2000 2200 2400 $300,000,0002600 2800 3000 3200 $350,000,0003400 3600 3800 4000 $400,000,0004200 $450,000,000 $500,000,000 $550,000,000

2017 2018 2019 2017 2018 2019

SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH 2019 REPORT PAGE 13 Copyright © 2020 Knowledge Commercialisation Australasia RESEARCH COMMERCIALISATION CASE STUDY 2 Faster, more accurate gold ore analysis with X-rays

PhotonAssay® uses high-energy X-rays to rapidly determine the gold content of mineral ores. This reduces sample turnaround from weeks to hours, enabling improved mineral processing control that may increase gold recovery by 1% to 3%, significantly raising the profitability of mining operations ¬– worth $2 billion per year to the gold industry alone.

PhotonAssay also eliminates the need for hazardous substances in the assay process, which improves environmental impacts and worker safety. Australia’s national science agency, CSIRO, developed this patented technology over 15 years, leading to the 2016 spin-out of Chrysos Corporation to commercialise it.

PhotonAssay has been deployed at two sites in Australia, and Chrysos has tested over 500,000 samples from over 60 customers including many international mines. The technology has been used to prepare industry- standard resource reports for companies including Novo Resources, Silver Lake Resources and Gold Road Resources.

Chrysos now employs 20 people, including scientists, software engineers, project managers and other operational roles. In late 2019, Chrysos facilitated the transaction of $15m of its shares by founding shareholders, including CSIRO. CSIRO uses the returns from its equity portfolio to invest in more breakthrough science.

Chrysos recently announced that they have signed a deal with Kirkland Lake Gold Ltd to install the technology at its Fosterville Mine, representing the first agreement signed directly with a mining company (rather than a laboratory services provider) and an important diversification of its customer base.

• An invention disclosure describes an invention (a technology or process) in detail and is used by the research organisation’s tech transfer team to determine the invention’s creators, novelty and potential for social impact and/or commercialisation. • Reported disclosures include those managed by other institutions Number(national of Inventionand international) Disclosures where 2017 at- 2019least one of the inventors is from the reporting institution.

Uni QLD Sydney Monas h UNSW Melbour ne CSIRO Curtin UniSA Adelaide QUT ANU Macqua rie RMIT UWA Wollongong Griffith Flinders Huds on Newcastle Note: WEHI Ranked by 2019 data. James Cook Tasmania Centenary Institute WSU

Telethon Kids La T robe Bionics Institute Westmead Institute Edith Cowan Federation ANSTO

0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160

2017 2018 2019

Uni QLD Newcastle Monas h Flinders NEW AND ACTIVE PATENT FAMILIES 2017-19 Melbour ne UNSW Sydney • New patents are applications first filed in 2019 – not follow-on filings (PCT, National, Continuation etc) – and are most likely to be Provisional applications. ANU • Active patents were filed in or before 2019 and have not expired. • A patent family comprises all patent applications and follow-on filings for a single invention. UWA • Reported patent families include applications filed by other institutions (both national and international) where at least one of the inventors is from the reporting institution. Adelaide ANSTO Curtin Tasmania Patent ApplicationsNEW Filed PATENT for New FAMILIES Patent Families 2017-2019 ActiveACTIVE Patent PATENT Families FAMILIES2017-2019

QUT UNSW Monas h Monas h Uni QLD Telethon Kids Melbour ne Sydney Sydney UNSW Griffith Uni QLD UWA Macqua rie Adelaide Adelaide RMIT Melbour ne UniSA Griffith ANU UniSA James Cook WEHI ANU RMIT Macqua rie Macqua rie La T robe QUT Griffith The following CSIRO data have WEHI Newcastle Wollongong Newcastle WEHI been excluded from these graphs RMIT UWA UniSA due to their magnitude: MLA Curtin WSU Flinders QUT Bionics Institute ANSTO 2017 78 new, 692 active James Cook Curtin La T robe 2018 56 new, 686 active Westmead Institute Bionics Institute Huds on WSU Tasmania 2019 68 new, 679 active Southern Queensland Wollongong Wollongong La T robe MLA Edith Cowan Huds on Flinders Tasmania Edith Cowan Note: Centenary Institute Southern Queensland Huds on Ranked by 2019 data. Telethon Kids Westmead Institute Black Dog Institute James Cook Telethon Kids Federation Centenary Institute Westmead Institute Centenary Institute WSU ANSTO Bionics Institute Southern Queensland Edith Cowan Federation

Federation 0 5 10 15 20 25 30 35 40 45 50 55 60 0 25 50 75 100 125 150 175 200 225 250 275 300 325 350

2017 2018 2019 $- $50,000,000 $100,000,0002017 2018 $150,000,0002019 $200,000,000 $250,000,000 $300,000,000 $350,000,000 $400,000,000 $450,000,000 $500,000,000 $550,000,000

2017 2018 2019

Uni QLD Newcastle Monas h NEW AND ACTIVE NON-PATENTED IP 2017-19 Flinders Melbour ne UNSW • This includes all IP that is not, nor intended to be, the subject of a patent but is intended for commercialisation, such as plant breeders’ rights, confidential know-how, registered designs, circuit layouts, trade secrets, software, trademarks, apps etc. Sydney • It includes IP from other institutions (national and international) where at least one of the creators or inventors is from the reporting institution. ANU • It excludes copyright and IP such as know-how that is included with a patent as part of a commercial LOA. UWA • New non-patented IP was first identified in 2019. Active non-patented IP was identified in or before 2019.

Adelaide New NonNEW-Patented NON-PATENTED Technologies IP 2017-2019 ANSTO Uni QLD Curtin CSIRO Tasmania Southern Queensland Active Non-PatentedACTIVE NON-PATENTED Technologies IP2017-2019 WEHI QUT Sydney CSIRO Telethon Kids Adelaide Uni QLD Melbour ne Sydney Griffith Macqua rie UNSW MLA Macqua rie Curtin Adelaide UniSA UniSA La T robe La T robe Southern Queensland WEHI WEHI Tasmania Melbour ne La T robe Monas h Tasmania Wollongong Huds on UniSA UWA Newcastle RMIT Macqua rie Curtin Monas h Black Dog Institute* WSU Flinders RMIT James Cook James Cook Wollongong UNSW Notes: Huds on Newcastle UWA Ranked by 2019 data. WSU Black Dog Institute* Southern Queensland Wollongong QUT * Financial year data Edith Cowan RMIT Telethon Kids Huds on was reported instead of Centenary Institute James Cook QUT calendar year data. Flinders Telethon Kids Black Dog Institute Centenary Institute ANU Federation Westmead Institute ANSTO Centenary Institute ANU Bionics Institute WSU 0 10 20 30 40 50 ANSTO60 70 Federation 2017 2018 2019 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 $- $50,000,000 $100,000,000 $150,000,000 $200,000,000 $250,000,000 $300,000,000 $350,000,0002017 2018 2019 $400,000,000 $450,000,000 $500,000,000 $550,000,000 2017 2018 2019

SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH 2019 REPORT PAGE 17 Copyright © 2020 Knowledge Commercialisation Australasia RESEARCH COMMERCIALISATION CASE STUDY 3 Aussie varnish protects international masterpieces

Cautious and discerning art conservators use specialist varnishes made to exacting standards to preserve artworks, including masterpieces worth hundreds of millions of dollars. In 2014, the industry-leading MS2A varnish – developed in the UK in 1959 – went out of production and most of the technical knowledge behind it was lost.

In 2016, with MS2A stocks dwindling fast, the National Gallery of Victoria (NGV) approached the CSIRO about producing more. CSIRO researchers applied world-leading chemical expertise to develop a new, improved varnish called MS3.

After studying published information about the chemical structure of MS2A resin and working closely with NGV conservators, the CSIRO chemists were first able to recreate and then enhance the varnish by utilising flow chemistry, where a chemical reaction occurs in a controlled, continuously flowing stream. MS3 has better clarity and chemical stability than older synthetic and natural resins and can be produced with greater consistency.

As a niche, low-volume but high-value product, Melbourne-based chemical manufacturer Boron Molecular saw the opportunity MS3 presented, purchased the licence and commenced commercial production in 2019. MS3 is now being used in prominent galleries and museums all over the world, to protect valuable paintings for the benefit and appreciation of future generations.

Uni QLD Newcastle Monas h NEW AND ACTIVE LICENCES, OPTIONS AND ASSIGNMENTS (LOAs) 2017-19 Flinders

Melbour ne • LOAs count only when new IP is created. New LOAs commenced in 2019. Active LOAs commenced in or before 2019. UNSW • Counted separately: each non-exclusive agreement; each new, stand-alone technology added to an existing LOA or in a multiple licence agreement. Sydney • Counted only once: each commercial deal for a stand-alone technology (i.e. after an option has been signed, this is not counted again when the licence is exercised, nor when the IP is assigned) and multiple personal-use licences for a software product. ANU • Excluded: Copyright, Material Transfer Agreements, licences granting researchers freedom to operate under a research contract, provisions for the use of institutional background UWA IP (unless this is the only IP in the LOA). New Commercial LOAs 2017-2019 Adelaide NEW LOAs ANSTO Macqua rie UNSW ACTIVE LOAs Curtin CSIRO Active Commercial LOAs 2017-2019 MLA Tasmania UNSW La T robe QUT CSIRO Sydney Melbour ne Telethon Kids Monas h Macqua rie Uni QLD Monas h Griffith Adelaide ANU Macqua rie Melbour ne Sydney ANU Uni QLD UniSA ANSTO MLA Adelaide WEHI WEHI WEHI Curtin La T robe La T robe UniSA UWA Wollongong QUT QUT UWA UniSA RMIT Huds on Curtin Notes: Wollongong Tasmania WSU Ranked by 2019 data. RMIT Flinders James Cook Black Dog Institute* Huds on Wollongong Tasmania * Financial year data Huds on RMIT Newcastle was reported instead of Southern Queensland ANSTO Westmead Institute James Cook calendar year data. Edith Cowan Southern Queensland Newcastle James Cook Black Dog Institute* Centenary Institute Centenary Institute Telethon Kids Black Dog Institute Flinders Centenary Institute Telethon Kids Westmead Institute Westmead Institute Bionics Institute WSU Edith Cowan Bionics Institute 0 10 20 30 40 50 60 70 80 90 100 110 Bionics120 Institute130 140 150 160 170 Southern Queensland Federation 2017 2018 2019 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 $- $50,000,000 $100,000,000 $150,000,000 $200,000,000 $250,000,000 $300,000,000 $350,000,000 $400,000,000 $450,000,000 $500,000,000 $550,000,000 2017 2018 2019 2017 2018 2019 SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH 2019 REPORT PAGE 19 Copyright © 2020 Knowledge Commercialisation Australasia Research Income 2017-2019

Uni QLD Newcastle Monas h COMMERCIALISATION REVENUE 2017-19 Flinders Melbour ne UNSW • Commercialisation revenue is the gross amount of income from all LOAs, material transfers and sales of products or services based on a research organisation’s expertise or IP, plus Sydney cashed-in equity, minus any cost of acquiring the equity. • Excluded: research funding, copyright income, non-cash value exchanged for equity holdings, value of equity not cashed-in, patent expense reimbursement, consultancies and ANU contract research – unless or until new IP is created. UWA Research Commercialisation Income 2017-2019 $6.0M $6.5M $7.0M $0.5M $1.0M $1.5M $2.0M $2.5M $3.0M $3.5M $4.0M $4.5M $5.0M $5.5M Adelaide UWA ANSTO Sydney Curtin Adelaide Tasmania Melbour ne QUT Griffith Telethon Kids UNSW ANU Griffith Notes: Macqua rie Ranked by 2019 data. Macqua rie MLA * Financial year data was reported instead of calendar year data. UniSA Black Dog Institute* # Only revenue from LOAs was reported. WEHI UniSA La T robe Curtin Wollongong Bionics Institute Huds on RMIT Data from the top four institutions have been graphed separately La T robe below due to their magnitude. In 2017, Walter and Eliza Hall WSU WSU Research CommercialisationInstitute of MedicalIncome 2017Research-2019 (WEHI) made a landmark deal worth James Cook Flinders # WEHI, CSIRO,$325 Uni million QLD, Griffith from &the Monash partial sale of royalty rights in anti-cancer Huds on RMIT treatment venetoclax – a result of collaboration between WEHI and companies Genentech and AbbVie. Southern Queensland QUT CSIRO* Edith Cowan James Cook Tasmania Centenary Institute WEHI Southern Queensland Black Dog Institute Telethon Kids Westmead Institute Uni QLD Newcastle Bionics Institute Edith Cowan Monas h Federation Centenary Institute

$0 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 $- $3,500,000 $50,000,000$50M$4,000,000 $100,000,000$100M$4,500,000 $150,000,000$150M$5,000,000 $5,500,000 $200,000,000$200M $6,000,000 $250,000,000$250M* Financial year$6,500,000 vs calendar $300,000,000$300M year $7,000,000 $350,000,000$350M $- $50,000,000 $100,000,000 $150,000,000 $200,000,000 $250,000,000 $300,000,000 $350,000,0002017 2018 2019 $400,000,000 $450,000,000 $500,000,000 $550,000,000 2017 2018 2019 2017 2018 2019

Uni QLD Newcastle Monas h Flinders NEW AND ACTIVE START-UP AND SPIN-OUT COMPANIES 2017-19 Melbour ne UNSW • Spin-out and start-up companies are founded through licensing or assignment of IP. Sydney • Spin-outs are launched by the research organisation. Start-ups are launched by other parties through licensing or assignment of IP. ANU • New companies were incorporated in 2019. Active companies were incorporated in or before 2019. A company is active when it has sufficient financial resources to operate and UWA make progress toward stated business goals. Adelaide New Start-NEWup & START-UPS Spinout Companies AND SPIN-OUTS 2017-2019 Active ACTIVEstart-up START-UPS & spinout AND companies SPIN-OUTS 2017-2019 ANSTO Sydney Uni QLD Curtin Adelaide Sydney Tasmania UNSW UNSW QUT CSIRO CSIRO Monas h Telethon Kids Wollongong UniSA UWA Griffith Newcastle Melbour ne Macqua rie Uni QLD UniSA UniSA UWA ANU WEHI ANU Curtin La T robe Monas h Adelaide Wollongong Macqua rie WEHI Tasmania RMIT Melbour ne Tasmania Flinders WSU RMIT QUT Note: James Cook La T robe Macqua rie Ranked by 2019 data. Huds on Flinders Bionics Institute Southern Queensland Curtin Griffith Edith Cowan Bionics Institute Telethon Kids La T robe Centenary Institute QUT James Cook James Cook Black Dog Institute WEHI ANSTO Westmead Institute Huds on Wollongong Bionics Institute Telethon Kids Huds on Federation Edith Cowan 0 1 2 3 4 5 6 7 8 9 Centenary Institute $- $50,000,000 $100,000,000 $150,000,0002017 2018 2019 $200,000,000 $250,000,000 $300,000,000 $350,000,000 $400,000,000 $450,000,000 $500,000,000 $550,000,000 0 5 10 15 20 25 30 35 2017 2018 2019 2017 2018 2019

SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH 2019 REPORT PAGE 21 Copyright © 2020 Knowledge Commercialisation Australasia Our mission is to give a voice to people who cannot verbalise their pain.

RESEARCH COMMERCIALISATION CASE STUDY 4 Giving a voice to people who can’t verbalise their pain

85 percent of aged care residents with dementia experience pain but many cannot verbalise it and so express their suffering through difficult behaviour. Instead of pain relief, they are often given anti-psychotic drugs with side- For more information,effects go online including www.painchek.com sedation that lead to falls, extended hospital stays, acute confusion and premature death.

To prevent this cascade, the PainChek® app – derived from Curtin University research – uses AI to recognise micro facial expressions of pain and a patented assessment system to objectively calculate a severity score. Carers can quickly assess patients from a safe distance, manage their pain appropriately, reduce behavioural issues and increase quality and length of life. The app seamlessly integrates with healthcare management systems to ensure best practice.

Responding to urgent market need – the current estimate of 50 million people with dementia is projected to rise to 152 million by 2050 – ePAT Pty Ltd was established in 2014 through private investment and listed as PainChek Ltd on the ASX in 2016. A $5 million Federal Government grant in late 2019 has made the app available to 100,000 people living with dementia in residential aged care across Australia. By March 2020, 175 healthcare providers and 588 facilities were licensed to use the app and had completed more than 100,000 clinical pain assessments.

PainChek has expanded to New Zealand, Singapore and the UK and plans to enter Europe and the US. Although Curtin University has sold its shares in the company, its researchers continue to work with PainChek through a contractual agreement. In future, PainChek could also be used in hospitals, primary care and at home, and for non-verbal children and people with delirium, disabilities, or neuromuscular disorders or post-stroke.